U.S. President Donald Trump’s threats to slap tariffs on medicines could rattle an industry that has become a cornerstone of ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Stock analysts noted Natco Pharma’s missed consensus Q3 estimates on both revenue and Ebitda margin fronts due to lack of ...

In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...

West Pharmaceutical (WST) delivered earnings and revenue surprises of 4% and 1.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.04 per share a year ago. These ...

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $1.73. This compares to loss of $1.72 per share a year ago. These ...

Pioneering license agreement with BrainTransporter signed with BMS worth up to USD 1.35 billion plus royalties Events during the fourth quarter 2024 The Australian Medicines Agency (TGA) decided not ...

Zoetis is the undisputed leader in the global animal health industry, and we believe it possesses the widest moat of all the competitors. Zoetis has set itself apart based on its impressive innovation ...

The new 25% tariffs on aluminium & steel, along with proposed increases in other areas, are sending shockwaves through global industries, particularly in the Asia-Pacific region. As companies face ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...